Ahlin A, Junthé T, Hassan M, Nybäck H
Department of Clinical Neuroscience, Karolinska Hospital, Stockholm, Sweden.
Int Psychogeriatr. 1995 Spring;7(1):75-83.
Fourteen patients suffering from dementia of the Alzheimer type were treated with tacrine (tetrahydroaminoacridine, THA) for 1 year in an open trial. Clinical results were evaluated every third month with neuropsychological tests and rating scales. During the dose-finding, two patients were temporarily withdrawn from medication and one patient was excluded because of elevated levels of liver enzymes. With individualized doses the treatment caused few side effects. Plasma levels of THA varied substantially among patients and correlated with elevation of liver enzymes but not with clinical response. Two patients showed a gradual increase in plasma levels of THA despite unchanged doses. Although results of the neuropsychological tests and clinical ratings were mostly negative, the study indicates that THA can be administered safely for prolonged periods of time. Clinical observations and dose-titration strategy in relation to side effects are discussed.
在一项开放性试验中，对14例阿尔茨海默型痴呆患者使用他克林（四氢氨基吖啶，THA）进行了为期1年的治疗。每三个月用神经心理学测试和评定量表评估临床结果。在剂量探索阶段，两名患者暂时停药，一名患者因肝酶水平升高被排除。采用个体化剂量治疗副作用较少。患者之间THA的血浆水平差异很大，且与肝酶升高相关，但与临床反应无关。两名患者尽管剂量不变，但THA的血浆水平逐渐升高。尽管神经心理学测试和临床评定结果大多为阴性，但该研究表明THA可长期安全给药。讨论了与副作用相关的临床观察和剂量滴定策略。
